Brief: Alzpath And Quanterix Expand Strategic Licensing Agreement To Advance Next Generation Alzheimer's Disease Biomarker Research
07/10/2026 13:48
BRIEF-Alzpath And Quanterix Expand Strategic Licensing Agreement To Advance Next Generation Alzheimer's Disease Biomarker Research Oct 7 (Reuters) - Quanterix Corporation QTRX.O:
ALZPATH AND QUANTERIX EXPAND STRATEGIC LICENSING AGREEMENT TO ADVANCE NEXT GENERATION ALZHEIMER'S DISEASE BIOMARKER RESEARCH
Source text: ID:nPn9nSPzSa
Further company coverage: QTRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quanterix
See all newsBrief: Alzpath And Quanterix Expand Strategic Licensing Agreement To Advance Next Generation Alzheimer's Disease Biomarker Research
Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Quanterix Corporation expected to post a loss of 46 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 46 cents a share - Earnings Preview